cytochrome c oxidase subunit 7A1Genealiases: COX7A · COX7AH · COX7AM
Q-omics provides the consensus-scored COX7A1 profile across patient tissues and cancer cell-line models. COX7A1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, COX7A1 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, COX7A1 protein abundance shows 26,341 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight UVM, BLCA, and HNSC as cancer lineages where COX7A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COX7A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COX7A1 survival associations across molecular data types. COX7A1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COX7A1 RNA expression–survival associations across cancer types. High COX7A1 expression shows unfavorable associations in UVM and LUSC, but favorable associations in UCEC, ACC, MESO and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for COX7A1 RNA expression.
This table summarizes COX7A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for COX7A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COX7A1 shows lower tumor expression in BLCA, KIRP, LUAD, UCEC, LUSC and HNSC. The BLCA box plot shows higher COX7A1 RNA expression in normal versus tumor tissue (log2 FC = −3.900, t-test p < 0.001).
This table shows molecular features associated with COX7A1 in patient tissues and cancer cell lines. In patient samples, COX7A1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, COX7A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
